Table 2.
APRI Score at Baseline (n = 1707) and at 12–24 Months (n = 1106)
| APRI Score | Baseline |
12–24 Months Post-ART |
||||||
|---|---|---|---|---|---|---|---|---|
| All (n = 1707) | HIV Monoinfected (n = 1566) | HBV/HIV Coinfected (n = 141) | P Value | All (n = 1106) | HIV Monoinfected (n = 1050) | HBV/HIV Coinfected (n = 56) | P Value | |
| APRI, median (IQR) | 0.38 (0.22–0.79) | 0.37 (0.22–0.77) | 0.57 (0.32–1.08) | <.001 | 0.41 (0.23–0.77) | 0.40 (0.22–0.77) | 0.50 (0.28–0.93) | .05 |
| APRI > 1.5, n (%) | 156 (9.1) | 136 (8.7) | 20 (14.2) | .03 | 56 (5.1) | 51 (5.0) | 5 (5.8) | .74 |
| APRI > 2, n (%) | 90 (5.3) | 77 (4.9) | 13 (9.2) | .03 | 26 (2.4) | 22 (2.2) | 4 (4.7) | .14 |
Abbreviations: APRI, AST-to-platelet ratio index; ART, antiretroviral therapy; HBV, hepatitis B infection; HIV, human immunodeficiency virus; IQR, interquartile range.